An Integrated Study Of Acyclic Nucleoside Phosphonates As Antimalarial Drugs
Funder
National Health and Medical Research Council
Funding Amount
$500,544.00
Summary
Malaria is one of the most serious infectious diseases today. Because of increasing resistance to existing medicines, new drugs are now needed. The therapeutic agents we will develop target the principal species responsible for human malaria are Plasmodium falciparum and vivax. Specifically, the compounds will prevent the parasite from replicating and are related in structure to those compounds in use to treat viral infections including AIDS.
Enhancing The Immune Response To Disordered Malaria Antigens
Funder
National Health and Medical Research Council
Funding Amount
$643,739.00
Summary
Half of the worlds population live at risk of malaria, and the disease kills half a million people a year, predominantly young children. Despite recent progress, a vaccine with the efficacy required to help control and ultimately eradicate malaria remains out of reach. This project studies an important class of proteins likely to form part of a future malaria vaccine, and will develop new ways to improve their effectiveness as vaccine components.
The Development Of Novel Antibody Constructs And Peptides To Prevent Pathogenic Modulation Of The Immune Response
Funder
National Health and Medical Research Council
Funding Amount
$335,825.00
Summary
The current lack of effective vaccines, as well as the emergence of drug resistance, underpins the need for the development of novel therapeutics to treat bacterial infections and malaria. In this project, I will be using computer-based molecular modelling techniques to design novel antimicrobial treatments.